$SXTP Income Statement | Understand Stock

$SXTP

$0.87 -$0.00 (0.25%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023
Product Revenues – net of Discounts and Rebates
Product Revenues – net of Discounts and Rebates
Total product Revenues – net of Discounts and Rebates
Cost of Revenues
Gross Profit
Research Revenues
Net (Loss) Revenue
Net Revenue
Operating Expenses:
Research and Development
General and Administrative Expenses
Total Operating Expenses
Loss from Operations
Interest Expense
Derivative Expense
Change in Fair Value of Derivative Liabilities
Change in Fair Value of Promissory Note
Change in Fair Value of Derivative Liabilities
Other Income, net
Total Interest and Other Income (Expense), net
Loss from Operations before Provision for Income Taxes
Provision for Income Taxes (Note 9)
Net Loss including Noncontrolling Interest
Unrealized Foreign Currency Translation Gain (Loss)
Unrealized Foreign Currency Translation Gain (Loss)
Total Comprehensive Loss
Net (Loss) Income – Noncontrolling Interest
Net Loss – Noncontrolling Interest
Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc.
Cumulative Dividends on Series A Preferred Stock
Net Loss - attributed to common stockholders
Net Loss per Common Share
Basic (in Dollars per share)
Diluted (in Dollars per share)
Weighted Average Number of Common Shares Outstanding
Basic (in Shares)
Diluted (in Shares)
Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc.

Comments